➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Express Scripts
Merck
Boehringer Ingelheim

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for ASLAN001

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ASLAN001?

ASLAN001 is an investigational drug.

There have been 11 clinical trials for ASLAN001. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2017.

The most common disease conditions in clinical trials are Biliary Tract Neoplasms, Stomach Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Aslan Pharmaceuticals, National University Hospital, Singapore, and National Cancer Centre, Singapore.

There are eight US patents protecting this investigational drug and fifty-four international patents.

Recent Clinical Trials for ASLAN001
TitleSponsorPhase
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract CancerAslan PharmaceuticalsPhase 2
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)Aslan PharmaceuticalsPhase 2/Phase 3
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract CancerAslan PharmaceuticalsPhase 2/Phase 3

See all ASLAN001 clinical trials

Clinical Trial Summary for ASLAN001

Top disease conditions for ASLAN001
Top clinical trial sponsors for ASLAN001

See all ASLAN001 clinical trials

US Patents for ASLAN001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASLAN001   Start Trial Quinazoline analogs as receptor tyrosine kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
ASLAN001   Start Trial Combination therapy comprising varlitinib and an anticancer agent ASLAN Pharmaceuticals PTE LTD (Singapore, SG)   Start Trial
ASLAN001   Start Trial Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof RACE ONCOLOGY LTD. (Melbourne, AU)   Start Trial
ASLAN001   Start Trial Quinazoline analogs as receptor tyrosine kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
ASLAN001   Start Trial Quinazoline analogs as receptor tyrosine kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
ASLAN001   Start Trial Quinazoline analogs as receptor tyrosine kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
ASLAN001   Start Trial Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof RACE ONCOLOGY LTD. (West Perth, AU)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASLAN001

Drugname Country Document Number Estimated Expiration Related US Patent
ASLAN001 Argentina 045378 2023-08-14   Start Trial
ASLAN001 Australia 2004264937 2023-08-14   Start Trial
ASLAN001 Australia 2004277722 2023-08-14   Start Trial
ASLAN001 Brazil PI0413565 2023-08-14   Start Trial
ASLAN001 Canada 2535614 2023-08-14   Start Trial
ASLAN001 Chile 2004002066 2023-08-14   Start Trial
ASLAN001 China 102432552 2023-08-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Express Scripts
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.